eli lilly retatrutide phase 3 trial Shows 28% Weight Loss in 80 Weeks Eli Lilly's Phase 3 clinical

All of life is a balance between antioxidants and oxidants

Findings from two related phase 2 clinical trials looking at the novel triple-hormone receptor agonist retatrutide were presented during a late-breaking symposium at the 83rd Scientific Sessions

This broader detoxification role is relevant in the hormonal health context because estrogen metabolism is not the only source of reactive compounds that the glutathione system must manage

Retatrutide plus exercise and nutrition optimization Adding structured resistance training and optimized protein intake to a retatrutide protocol may address the muscle preservation concern without the risks of adding tesamorelin